Immunohistochemistry expression of tumor markers CD34 and P27 as a prognostic factor of clinically localized prostate adenocarcinoma after radical prostatectomy;Expressão imunohistoquímica do marcador tumoral CD34 e P27 como fator prognóstico em adenocarcinoma de próstata clinicamente localizado após prostatectomia radical

Revista do Colegio Brasileiro de Cirurgioes

Volumn 37, Issue 5, 2010, Pages 338-344

  Nassif, Aissar Eduardo ^a   Filho, Renato Tâmbara ^b  

^a Department of Medicine and Psychology   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Cd34 antigens; Neoplasms of the prostate; Prostatectomy; Rex gene products

Indexed keywords

EID: 78650824257     PISSN: 01006991     EISSN: 18094546     Source Type: Journal    
DOI: 10.1590/s0100-69912010000500006     Document Type: Article

References (44)

1. Ercole B, Marietti SR, Fine J, Albertsen PC. Outcome following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol. 2008; 180(4):1336-9; discussion 1340-1. Epub 2008 Aug 15.
2. Kuo NW, Lin HC, Lee HC. Physician clinical experience and inappropriate prostate specific antigen screening: evidence from an Asian country. J Urol. 2008; 180(5):1954-8; discussion 1958. Epub 2008 Sep 17.
3. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435-48. Epub 2008 Feb 4. Erratum in: Ann Intern Med. 2008;148(1):888.
4. INSTITUTO NACIONAL DE CÂNCER. Estimativa 2008 - Incidência de câncer no Brasil. Rio de Janeiro: INCA; 2008.
5. Klein EA, Bianco F, Serio AM, Eastham JA, Kattan MW, Pontes JE, et al. Surgeon experience in strongly associated with biochemical recurrence after racial prostatectomy for all preoperative risk categories. J Urol. 2008;179(6):2212-7.Epub 2008 Apr 18.
6. Neal DE. Can we accurately identify men with low risk prostate cancer? J Urol. 2008;180(4):1217-18. Epub 2008 Aug 15.
7. Simone NL, Singh AK, Cowan JE, Soule BP, Carolli PR, Litwin MS. Pretreatment predictors of death from other causes in men with prostate cancer. J Urol. 2008; 180(6):2447-51; discussion 2451-2. Epub 2008 Oct 19.
8. Billis A, Guimarães MS, Freitas LLL, Meirelles L, Magna LA, Ferreira U. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol. 2008; 180(2):548-52; discussion 552-3. Epub 2008 Jun 11.
9. Liska J, Repiska V, Polak S, Varga I, Blasko M, Macejova D, et al. Prostate tumors-histological classification and molecular aspects of prostate tumorigenesis. Endocr Regul. 2007;41(1):45-57.
10. Arlen PM, Bianco F, Dahut WL, D́amico A, Figg WD, Freedland SJx, /xet-alet al/et-al. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol. 2008;179(6):2181-5; discussion 2185-6. Epub 2008 Apr 18.
11. Freedland SJ, Moul JW. Prostate specific antigen recurrence after definitive therapy. J Urol. 2007;177(6):1985-91.
12. Doganavsargil B, Simsir A, Boyaciogluc H, Cal C, Hekimgli M. A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int. 2006;97(3):644-8.
13. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarkers approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Nat Cancer Inst. 2003;95(9):661-8.
14. Dhir R. Prostate cancer biobanking. Curr Opin Urol. 2008;18(3):309-14.
15. Concato J, Jaind D, Li WW, Risch HA, Uchio EM, Wells CK. Molecular markers and mortality in prostate cancer. BJU Int. 2007;100 (6):1259-63. Epub 2007 Sep 10.
16. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Nat Cancer Inst. 1997;89(2):158-65.
17. Jin S. p53. Autophagy and tumor suppression. Autophagy. 2005;1(3):171-3.Epub 2005 Oct 21.
18. Mohaptra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res. 2005;65(17):7717-23.
19. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993; 143(2):401-9.
20. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol. 1998;160(2):459-65.
21. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis. 2002;5(2):123-7.
22. Izawa JI, Dinney CP. The role of angiogenesis in prostate and other urologic cancer: a review. CMAJ. 2001;164(5):663-70.
23. Charlesworth PJ, Harris AL. Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Prac Urol. 2006;3(3):157-69.
24. Taille A, Katz AE, Bagiella E, Buttyan R, Sharir S, Olsson CA, et al. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. Am J Clin Pathol. 2000;113(4):555-62.
25. Arakawa A, Soh S, Chakraborty S, Scardino PT, Wheeler TM. Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for factor VIII-related antigen and CD34 antigen). Prostate Cancer Prostatic Dis. 1997;1(1):32-8.
26. Pang RW, Poon RT. Clinical implication of angiogenesis in cancers. Vasc Heal Risk Manag. 2006;2(2):97-108.
27. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, et al. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology. 1994;44(6):869-75.
28. Borre M, Offersen BV, Nerstrøm B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer. 1998, 78(7):940-4.
29. Halvorsen O, Haukaas S, Høisaeter P, Akslen LA. Independent prognostic importance of microvessel density in clinically localized prostate cancer. Anticancer Res. 2000;20(5C):3791-9.
30. Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology. 1999;53(3):542-7.
31. Strohmeyer D, Rössing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate. 2000;42(1):26-33.
32. Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999;54(3):479-85.
33. Krupski T, Petroni GR, Frierson HF Jr, Theodorescu JU. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology. 2000;55(5):743-9.
34. Barbareschi M. p27 expression, a cyclin dependent kinase inhibitor in breast carcinoma. Adv Clin Path. 1999;3(4):119-27.
35. Tsuchiya A, Zhang GJ, Kanno M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol. 1999;70(4):230-4.
36. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 1999;59(3):684-8.
37. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schröder FH, van der Kwast TH. Prognostic value of cell cycle proteins p27 (kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol. 2000;164(6):2156-61.
38. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, DeKernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159(3):941-5.
39. Yu DS. Apoptosis-related markers for predicting progression of prostate cancer. J Chin Med Assoc. 2007;70(1):3.
40. Nguyen PL, Lin DI, Lei J, Fiorentino M, Mueller E, Weinstein MH, et al. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol. 2009 May 16. [Epub ahead of print]
41. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Tenta R, Koutsilieris M. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo. 2005;19(5):911-20.
42. Zheng XY, Ding W, Xie LP, Chen ZD. [Correlation of Skp2 and P27kip1 protein expression and clinicopathological features of prostate cancer]. Ai Zheng. 2004; 23(2):215-8.
43. Roy S, Singh RP, Agarwal C, Siriwardana S, Sclafani R, Agarwal R. Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle. 2008;7(12):1828-1835. Epub 2008 Jun 30.
44. Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B, et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Can Res. 2003;9(7):2613-9.